Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1CNS 1

Conditions

Glioblastoma 18Glioma 11Neoplasms 6Brain Neoplasms 6Astrocytoma 6Neuroblastoma 4Sarcoma, Ewing 3Gliosarcoma 3Sarcoma 2Rhabdomyosarcoma 2Recurrence 2Pancreatic Neoplasms 2Medulloblastoma 2Diffuse Intrinsic Pontine Glioma 2Wilms Tumor 1Spinal Cord Neoplasms 1Rhabdoid Tumor 1Refractory Solid Tumors 1Prostatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Oligodendroglioma 1Neuroendocrine Tumors 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasm Metastasis 1Melanoma, Cutaneous Malignant 1Melanoma 1Lymphoma, Follicular 1Hepatoblastoma 1Ganglioneuroblastoma 1

Interventions

Cyclophosphamide 11Rituximab 10Prednisone 8Lenalidomide 8Vincristine 7Doxorubicin 7Bendamustine Hydrochloride 6obinutuzumab 5Magnetic Resonance Spectroscopy 4fludarabine 3Whole-Body Irradiation 3Specimen Handling 3R-CHOP protocol 3Cyclosporine 3Biopsy 3zanubrutinib 2fludarabine phosphate 2Radiotherapy 2Prednisolone 2Peripheral Blood Stem Cell Transplantation 2Oxaliplatin 2Mycophenolic Acid 2Melphalan 2Gemcitabine 2Etoposide 2Cytarabine 2venetoclax 1umbralisib 1treosulfan 1tazemetostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Follicular × Temozolomide × 30 days × Clear all
NCT05765812 2026-05-28

A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma

Debiopharm International SA

Phase 1/2 Recruiting
116 enrolled
CNSLymphoid

Astrocytoma, Glioblastoma, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡